HK1066830A1 - Hiv- rt-nef-gag codon optimised dna vaccines hiv-rt-nef-gag - Google Patents

Hiv- rt-nef-gag codon optimised dna vaccines hiv-rt-nef-gag

Info

Publication number
HK1066830A1
HK1066830A1 HK04109687.5A HK04109687A HK1066830A1 HK 1066830 A1 HK1066830 A1 HK 1066830A1 HK 04109687 A HK04109687 A HK 04109687A HK 1066830 A1 HK1066830 A1 HK 1066830A1
Authority
HK
Hong Kong
Prior art keywords
hiv
nef
gag
dna vaccines
fragment
Prior art date
Application number
HK04109687.5A
Other languages
English (en)
Inventor
Andrew Beaton
Peter Franz Ertl
Gerald Wayne Gough
Andrew Lear
John Philip Tite
Catherine Ann Van Wely
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2001/004207 external-priority patent/WO2002024225A1/en
Priority claimed from GB0129604A external-priority patent/GB0129604D0/en
Priority claimed from GB0206462A external-priority patent/GB0206462D0/en
Priority claimed from PCT/EP2002/010592 external-priority patent/WO2003025003A2/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of HK1066830A1 publication Critical patent/HK1066830A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK04109687.5A 2001-09-20 2004-12-07 Hiv- rt-nef-gag codon optimised dna vaccines hiv-rt-nef-gag HK1066830A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/GB2001/004207 WO2002024225A1 (en) 2000-09-20 2001-09-20 Use of immidazoquinolinamines as adjuvants in dna vaccination
GB0129604A GB0129604D0 (en) 2001-12-11 2001-12-11 Novel compounds
GB0206462A GB0206462D0 (en) 2002-03-19 2002-03-19 Vaccines
PCT/EP2002/010592 WO2003025003A2 (en) 2001-09-20 2002-09-18 Hiv-gag codon-optimised dna vaccines

Publications (1)

Publication Number Publication Date
HK1066830A1 true HK1066830A1 (en) 2005-04-01

Family

ID=43927344

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04109687.5A HK1066830A1 (en) 2001-09-20 2004-12-07 Hiv- rt-nef-gag codon optimised dna vaccines hiv-rt-nef-gag

Country Status (7)

Country Link
KR (1) KR101067231B1 (de)
AT (1) ATE506439T1 (de)
DE (1) DE60239815D1 (de)
HK (1) HK1066830A1 (de)
MY (1) MY131949A (de)
TW (1) TWI329647B (de)
ZA (1) ZA200402189B (de)

Also Published As

Publication number Publication date
KR101067231B1 (ko) 2011-09-22
KR20040039387A (ko) 2004-05-10
ZA200402189B (en) 2005-07-27
TWI329647B (en) 2010-09-01
MY131949A (en) 2007-09-28
DE60239815D1 (de) 2011-06-01
ATE506439T1 (de) 2011-05-15

Similar Documents

Publication Publication Date Title
WO2003025003A3 (en) Hiv-gag codon-optimised dna vaccines
MY145614A (en) Vaccine
WO2000029561A3 (en) Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
BR0010361A (pt) Seq ências genÈmicas de neisseria e uso destas
MXPA05010007A (es) Replicones de alfavirus y construcciones auxiliares mejorados.
WO2002080851A3 (en) Chimeric vaccines
MXPA02006888A (es) Flavivirus recombinantes y metodos para utilizar los mismos.
GB2351290A (en) Retroviral delivery sytem
WO2005034992A3 (en) Hiv vaccines based on env of multiple clades of hif
TW200502245A (en) Vaccine
HK1066830A1 (en) Hiv- rt-nef-gag codon optimised dna vaccines hiv-rt-nef-gag
MXPA02012593A (es) Particulas de tipo virus del virus de la diarrea viral bovina.
AU5322800A (en) Cloned genone of infectious hepatitis c virus of genotype 2a and uses thereof
WO2003089571A3 (en) Ehrlichia canis genes and vaccines
DE69840326D1 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
ZA935117B (en) Anti-feline immunodeficiency virus (FIV) vaccines
GB0202569D0 (en) Delivery means
WO2002022663A3 (en) Stress resistant retroviruses
HUP0500099A2 (hu) Glükuronil C5-epimeráz, az azt kódoló DNS és ezek alkalmazása
EP1578772A4 (de) Cytokine und cytokinrezeptoren mit reduzierter immunogenität
HUP0001857A2 (hu) Bakteriális plazmidok
WO2001007625A3 (en) Ehrlichia canis genes and vaccines
WO2002038769A3 (de) Für expression in eukaryonten optimierte hpv 16-l1 und hpv 16-l2 kodierende dna-sequenzen
GB0120437D0 (en) Diabetic model
MX2023003651A (es) Virus de la diarrea epidemica porcina atenuado.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150918